NCT07808073RecruitingPhase 1
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1, Participant- and Investigator-Blind, Single-Ascending and Multiple- Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4329090 in Participants With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts. For each participant in Part A, the study will last about 10 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 5 nights along with 5 outpatient visits to the CRU. For each participant in Part B, the study will last about 21 weeks and will include 4 stays totaling 11 nights along with 14 outpatient visits to the CRU.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- First submitted
- 3 Sept 2026
- Start date
- 22 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT07808073
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 184
- From 22 Sept 2026 to the primary completion date, 30 Sept 2027
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have a known, clinically significant gastric emptying abnormality, have undergone weight loss surgery, or have had endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
- Have received any drugs from the incretins class within 90 days prior to screening.
- Have been treated within 3 months prior to screening or plan to be treated with prescription medications that promote weight loss.
- Intend to use any weight loss medications during study participation.
- Prior (within 6 months) or planned (during the study) device-based treatment use for obesity.
Other illness
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders.
- Have a history of chronic medical conditions involving the heart, liver, or kidneys.
- Have either
- ongoing asymptomatic bradycardia defined as less than 50 beats per minute at screening visit
- electrocardiogram (ECG) findings at screening visit of second-degree atrioventricular block or higher, or
- history of symptomatic bradycardia with uncorrected etiology, including diagnosis of sick sinus syndrome.
- Have an obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
- Have a history or presence of psychiatric disorders, within the last 2 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
Lab values
- Have any of the following:
- a diagnosis of hypocalcemia or hypercalcemia, or
- confirmed abnormal laboratory values for calcium and serum phosphorus.
- Have been diagnosed with type 1 or type 2 diabetes mellitus or have glycated hemoglobin A1c (HbA1c) greater than or equal to (≥) 6.5 percent (%) or 48 millimoles per mole (mmol/mol) at screening.
- Have taken any glucose-lowering medications, including insulin, in the past 3 months before screening.
Other
- Have an abnormal blood pressure and/or pulse rate at screening.
Who the study is looking for
- Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent.
- Are overtly healthy with no comorbidities related to body mass index (BMI).
- Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m², inclusive.
- Have had a self-reported stable weight for 3 months prior to screening.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Not yet recruiting |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.